

# M Raymond V Finlay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7852031/publications.pdf>

Version: 2024-02-01

17  
papers

3,000  
citations

567281

15  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

4414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8 <i>H</i> -purin-8-one Inhibitors of DNA-PK. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1295-1301.	2.8	0
2	Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs. <i>Clinical Cancer Research</i> , 2021, 27, 189-201.	7.0	106
3	Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13704-13718.	6.4	13
4	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- <i>a</i> ]pyridin-6-yl)amino]-9-(tetrahydro-2 <i>H</i> -pyran-4-yl)-7,9-dihydro-8 <i>H</i> -purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3461-3471.	6.4	47
5	AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. <i>Nature Communications</i> , 2019, 10, 5065.	12.8	195
6	Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6540-6560.	6.4	21
7	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. <i>Journal of Clinical Investigation</i> , 2019, 130, 258-271.	8.2	45
8	Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 885-896.	4.1	80
9	Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2326-2349.	6.4	24
10	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 1046-1061.	9.4	1,655
11	Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Sparing the Wild Type Form of the Receptor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8249-8267.	6.4	454
12	Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7025-7048.	6.4	201
13	Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5352-5359.	2.2	37
14	Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4163-4168.	2.2	28
15	Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4442-4446.	2.2	32
16	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5487-5492.	2.2	28
17	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6486-6489.	2.2	34